Larynx | Lip, Oral Cavity and Pharynx, Phase II
Single-Arm Phase II Trial of Dual Inhibition of EGFR With Afatinib and Cetuximab With Correlative Studies in the Second-Line Treatment of Recurrent or Metastatic Squamous Cell Cancers of the Head and Neck
Volunteers
Health Professionals
What is the purpose of this trial?
This is a single arm Phase II study for patients with recurrent or metastatic squamous cell carcinoma of the head and neck, who are previously treated with a platinum based regimen or with an immune checkpoint inhibitor. The primary objective is to evaluate the efficacy of the combination of cetuximab and afatinib.
- Trial withYale Cancer Center
- Ages18 years and older
- GenderBoth
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.
Principal Investigator
Sub-Investigators
- Agatha Hecht
- Alison Johnson
- Anca Bulgaru, MD
- Andrea Brennan
- Ashita Talsania, MRCP, MBBS
- Barbara Burtness, MD
- Benjamin Newton, MD
- Benjamin L. Judson, MD, MBA
- Beverly Drucker, MD, PhD
- Brittany Bordonaro
- Brooke Chaves
- Catherine Wei, MD
- D. Barry Boyd, MD, MS
- David Witt, MD
- Elan Gorshein, DO, JD, MPH
- Hari Deshpande, MD
- Harold Tara Jr, MD
- James Vredenburgh, MD
- Jane Kanowitz, MD
- Jason Haldas, MD
- Jaykumar Thumar, MBBS, MD
- Justin Persico, MD
- Karishma Mehra, MBBS
- Katherine Harvey, MD, MPH
- Kathleen Fenn, MD
- Kert Sabbath, MD, FACP
- Lynn Mastrianni
- Lynsey Teulings
- M. Sung Lee, MD
- Madeline Santiago
- Melissa Rasar Young, MD, PhD
- Michael Chiorazzi, MD, PhD
- Michael Cohenuram, MD
- Neal Fischbach, MD
- Pawan Karanam, MD
- Renee Moye
- Robert Legare, MD
- Sarah Carlson
- Sarah Thomen, APRN
- Saral Mehra, MD, MBA, FACS
- Stacey LaRosa
- Stephen Lattanzi, MD
- Su Hsien Lim, MD
- Vanna Dest
- Victor Chang, MD
- Vidya Kesavan
- Virginia Syombathy
- Wajih Kidwai, MD, FACP
- Last Updated03/21/2024
- Study HIC#1608018260